Xenon Pharmaceuticals Shares Plunge 25% After Pausing Azetukalner Depression Trials on Adverse Events

Xenon Pharmaceuticals fell roughly 22 to 25 percent in premarket trading on September 18, 2026, after the company voluntarily paused new enrollment in its Phase 3 studies of azetukalner in major depressive disorder and bipolar depression following adverse events. Barron's described it as the stock's worst single-day performance since 2017, with the safety signal casting a shadow over what had been the drug's most closely watched expansion beyond epilepsy.

The setback arrived alongside a separate, more constructive development: Xenon simultaneously submitted a new drug application for azetukalner in focal seizures, underscoring the dual-edged nature of relying on a single lead asset across multiple indications. The trial pause does not affect the NDA filing, but investors reacted overwhelmingly to the safety news.

Analysts were divided on how to interpret the pause. Deutsche Bank downgraded the stock to Hold from Buy and set a price target of $46, citing the safety concerns. Needham also cut its price target, though it maintained its rating. In contrast, H.C. Wainwright reiterated its existing rating and Stifel held its Buy recommendation after the trial pause, suggesting some on Wall Street view the selloff as an overreaction given the focal seizures NDA progress.